Pfizer Corporation

Other

Michael Stephen Pacey

Bernard Joseph Banks

Lee Richard Roberts

Peter Francis Leadlay

James Staunton

Graham Lunn

Jesus Cortes

Mark A Haxell

Nathan Anthony Logan Chubb

James John Eshelby

Darren John Schulz

Bernard Frank Bishop

David Austen Perry

The invention described herein relates to: the use of an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase in the manufacture of a composition for the treatment of acidosis; a method of treatment of rumen acidosis which comprises administration of an effective amount of an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase to a ruminant; a formulation suitable for the treatment of acidosis in an animal which comprises an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase in admixture with a suitable excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical/veterinary/farming practice; screening methods useful in the identification of a suitable inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase for the treatment of acidosis in a ruminant; a process for improving ruminant milk quality and/or quantity which comprises treatment of a ruminant with an effective amount of an inhibitor of bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase; a compound of the formula I: or veterinarily acceptable salt, solvate (including hydrate) or prodrug thereof; and processes to make an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase useful for the treatment of acidosis in a ruminant.

Treatment of rumen acidosis with &#x3b1;-amylase inhibitors

The invention described herein relates to: the use of an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase in the manufacture of a composition for the treatment of rumen acidosis; a method of treatment of rumen acidosis which comprises administration of an effective amount of an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase to a ruminant; a formulation suitable for the treatment of rumen acidosis in an animal which comprises an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase in admixture with a suitable excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical/veterinary/farming practice; screening methods useful in the identification of a suitable inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase for the treatment of acidosis in a ruminant; a process for improving ruminant milk quality and/or quantity which comprises treatment of a ruminant with an effective amount of an inhibitor of bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase; a compound of the formula I:or veterinarily acceptable salt, solvate (including hydrate) or prodrug thereof; and processes to make an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase useful for the treatment of acidosis in a ruminant.

Enzymatic oxidations

Erythromycins, particularly ones with novel C-13 substituents R1 (e.g. C -C cycloalkyl or cycloalkenyl groups) are prepared by fermenting suitable organisms in the presence of R CO H. A preferred organism is preferably containing an integrated plasmid capable of directing synthesis of desired compounds.

Erythromycins and process for their preparation

Isoxazole-sulfonamide endothelin antagonists

Erythromycins, particularly with C-13 substituents R1 (e.g. C,-C,cycloalkyl or cycloalkenyl groups) are prepared by fermenting suitable organisms in the presence of R,CO,H. A preferred organism is,preferably containing an integrated plasmid capable of directing synthesis of desired compounds.

A 5-oximino-25-substituted avermectin B1 or B2 monosaccharide of formula I herein has use in the treatment of parasitic infections in animals and humans. The compounds may be prepared from corresponding 5-keto substituted derivatives.

Antiparasitic agents related to the milbemycins and avermectins

Growing community of inventors

County of Kent, United Kingdom

Michael Stephen Pacey